Trinh Kieu The Loan, Lee Nae Yoon
Department of Industrial Environmental Engineering, Gachon University, 1342 Seongnam-daero, Sujeong-gu, Seongnam-si 13120, Korea.
Department of BioNano Technology, Gachon University, 1342 Seongnam-daero, Sujeong-gu, Seongnam-si 13120, Korea.
Pathogens. 2022 Sep 16;11(9):1057. doi: 10.3390/pathogens11091057.
Viability assessment is a critical step in evaluating bacterial pathogens to determine infectious risks to public health. Based on three accepted viable criteria (culturability, metabolic activity, and membrane integrity), current viability assessments are categorized into three main strategies. The first strategy relies on the culturability of bacteria. The major limitation of this strategy is that it cannot detect viable but nonculturable (VBNC) bacteria. As the second strategy, based on the metabolic activity of bacteria, VBNC bacteria can be detected. However, VBNC bacteria sometimes can enter a dormant state that allows them to silence reproduction and metabolism; therefore, they cannot be detected based on culturability and metabolic activity. In order to overcome this drawback, viability assessments based on membrane integrity (third strategy) have been developed. However, these techniques generally require multiple steps, bulky machines, and laboratory technicians to conduct the tests, making them less attractive and popular applications. With significant advances in microfluidic technology, these limitations of current technologies for viability assessment can be improved. This review summarized and discussed the advances, challenges, and future perspectives of current methods for the viability assessment of bacterial pathogens.
活力评估是评估细菌病原体以确定对公众健康的感染风险的关键步骤。基于三个公认的活力标准(可培养性、代谢活性和膜完整性),当前的活力评估可分为三种主要策略。第一种策略依赖于细菌的可培养性。该策略的主要局限性在于它无法检测到活的但不可培养(VBNC)的细菌。作为第二种策略,基于细菌的代谢活性,可以检测到VBNC细菌。然而,VBNC细菌有时会进入休眠状态,使它们停止繁殖和代谢;因此,无法基于可培养性和代谢活性检测到它们。为了克服这一缺点,已经开发了基于膜完整性的活力评估方法(第三种策略)。然而,这些技术通常需要多个步骤、庞大的仪器以及实验室技术人员来进行测试,这使得它们作为应用缺乏吸引力且不太受欢迎。随着微流控技术的重大进展,当前活力评估技术的这些局限性可以得到改善。本文综述并讨论了当前细菌病原体活力评估方法的进展、挑战和未来展望。